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Abstract
Background: Adenosine is involved in several neurological and behavioral disorders including alcoholism. In cultured cell
and animal studies, type 1 equilibrative nucleoside transporter (ENT1, slc29a1), which regulates adenosine levels, is known
to regulate ethanol sensitivity and preference. Interestingly, in humans, the ENT1 (SLC29A1) gene contains a non-
synonymous single nucleotide polymorphism (647 T/C; rs45573936) that might be involved in the functional change of
ENT1.
Principal Findings: Our functional analysis showed that prolonged ethanol exposure increased adenosine uptake activity of
mutant cells (ENT1-216Thr) compared to wild-type (ENT1-216Ile) transfected cells, which might result in reduced
extracellular adenosine levels. We found that mice lacking ENT1 displayed increased propensity to ethanol withdrawal
seizures compared to wild-type littermates. We further investigated a possible association of the 647C variant with
alcoholism and the history of alcohol withdrawal seizures in subjects of European ancestry recruited from two independent
sites. Analyses of the combined data set showed an association of the 647C variant and alcohol dependence with
withdrawal seizures at the nominally significant level.
Conclusions: Together with the functional data, our findings suggest a potential contribution of a genetic variant of ENT1 to
the development of alcoholism with increased risk of alcohol withdrawal-induced seizures in humans.
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Introduction
Alcohol use disorders affect approximately 4–5% of the world
population [1,2] and impose major public health and social
problems with substantial worldwide economic loss [3]. For the
addicted individuals, the recovery process can be deterred by
withdrawal symptoms such as alcohol withdrawal-induced seizures
[4]. On a neurochemical level, the withdrawal symptoms are
mainly attributed to an imbalance between inhibitory and
excitatory neurotransmitters. Alterations of GABA and glutamate
levels have been demonstrated to be major contributors of
withdrawal symptoms [5,6]. Recently, several lines of evidence
indicated that adenosine promotes GABA release, but inhibits
glutamate release in the central nervous system [7]. Consistently,
adenosine is known to mediate some aspects of alcohol-induced
behavior such as ataxia and hypolocomotion by depressing the
neuronal firing activity [8,9]. Moreover, adenosine exerts
anticonvulsant properties through adenosine receptors such as
A1 or A2A receptors [10,11,12]. Several preclinical and clinical
trials have suggested that the regulation of adenosine levels might
be effective in treating epileptic seizures [13,14,15].
Nucleoside transporters regulate adenosine levels across the
plasma membrane of neurons and glial cells [7]. In vitro studies
demonstrated that type 1 equilibrative nucleoside transporter
(ENT1) encoded by Slc29a1 gene is specifically inhibited by acute
exposure to alcohol, leading to increased extracellular adenosine
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levels. However, ENT1 is no longer inhibited by alcohol after
chronic alcohol treatment [16,17,18]. Our previous studies
showed that mice lacking ENT1 are less sensitive to the
intoxicating effects of ethanol, and consume more alcohol
compared to wild-type littermates [19,20]. We also found
increased glutamate neurotransmission in the striatum as a result
of the deficit of presynaptic A1 receptor function in the
glutamatergic neurons [19] or decreased glutamate uptake activity
via excitatory amino acid transporter type 2 (EAAT2) in astrocytes
[21]. ENT1 is an evolutionarily well-conserved membrane
transporter that contains few single nucleotide polymorphisms
(SNPs) [22]. After sequencing 200 DNA samples from subjects
with European ancestry, Osato et al. found only one nonsynon-
ymous SNP in ENT1, 647C (ENT1-216Thr; rs45573936), with a
minor allele frequency (MAF) of 0.021 [23]. The function of
human ENT1-216Thr in mammalian cells remained unknown.
The association between ENT1-216Thr and human psychopa-
thology including alcoholism has also not been studied. Here, we
investigated the role of ENT1-216Thr by utilizing three
approaches. First, since ENT1 is expressed in most cells, we
investigated the pharmacological role of human ENT1-216Thr in
primary cultured fibroblast cells derived from ENT1 null mice.
Second, we examined ethanol withdrawal seizures in ENT1-null
mice compared to wild type littermates. Finally, we tested for
association of the ENT1-216Thr variant with alcohol dependence
and alcoholism with withdrawal seizures.
Results
No Alterations in mRNA and Protein Expressions of ENT1-
216Thr
Since the 647C (ENT1-216Thr) is the only nonsynonymous
SNP (rs45573936) located in transmembrane 6 of human ENT1
(Figure 1A), which possibly alter the ENT1 function [23], we
decided to investigate the functional significance of the ENT1-
216Thr. We first examined the mRNA and protein expression in
mouse embryonic fibroblast (MEF) cells. We utilized MEF cells
isolated from ENT1 null mice to eliminate the effects of the
endogenous mouse ENT1. The MEF cells were transfected myc-
tagged ENT1-216Ile and 216Thr constructs. In a realtime RT-
PCR assay, the mRNA levels were similar between ENT1-216Ile
and 216Thr (Figure 1B, P.0.05). As shown in Figure 1C, protein
levels were also similar between ENT1-216Ile and 216Thr
(P.0.05).
Next we examined whether 216Thr alters protein expression in
the plasma membrane. Since it was demonstrated that mutations
in transmembrane domain 5 [24] and 8 [25] of ENT1 may alter
membrane expression of ENT1, we decided to examine whether
amino acid changes from isoleucine to threonine in the
transmembrane 6 of ENT1 alter membrane expression. Further-
more, the transmembrane 6 is directly linked to a large
cytoplasmic domain of the ENT1 which contains several
phosphorylation sites. To examine this possibility, we first added
enhanced green fluorescence protein (EGFP) to C-terminal part of
ENT1-216Ile and 216Thr. We used sodium-potassium ATPase as
a plasma membrane marker protein. We, however, found no
significant difference of membrane expression between ENT1-
216Ile and 216Thr (Figure 1D, P.0.05).
Prolonged Ethanol Treatment Reduced Binding Affinity,
but Increased Uptake Activity of the ENT1-216Thr
We investigated pharmacological properties of ENT1-216Thr
in transfected MEF cells using an ENT1-specific radioligand, [3H]
NBMPR [S-(p-nitrobenzyl)-6-thioinosine] as described [26]. As
shown in Figure 2A, we found that the equilibrium dissociation
constant (Kd) of ENT1-216Thr (1.4660.26 nM) was significantly
higher compared to ENT1-216Ile (0.8360.17 nM) (*P,0.05),
indicating that the substitution from isoleucine to threonine
reduces the binding affinity to NBMPR. On the other hand, the
maximal density of transporter sites (Bmax) was similar between
ENT1-216Ile (49126225.1 fmol/mg protein) and ENT1-216Thr
(50086213.2 fmol/mg protein) (P.0.05), which is consistent with
our Western and confocal microscope analysis in Figure 1. Next,
we examined the uptake activity after cells were incubated with
200 mM ethanol for 1 h or 24 h. Interestingly, the uptake activity
for both adenosine (Figure 2B) and inosine (Figure 2C) in cells
expressing mutant was significantly increased when cells were
Figure 1. Expression of ENT1-216Thr Variant. (A) A schematic of
the transmembrane structure of hENT1. The genetic variant of Ile216Thr
is located at transmembrane domain 6. Similar mRNA expression (B)
and protein expression (C) were found between ENT1-216Ile and
216Thr in transfected MEF cells. (D) Plasma membrane expression of
ENT1-216Thr (green) examined by a confocal microscopy. The sodium
potassium ATPase (red) was used for maker of plasma membrane. Ratio
of green fluorescence versus red one was similar (P.0.05, two-tailed t-
test). Scale bar = 10 mm. Statistical significance was calculated by two-
tailed t tests. All data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0016331.g001
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exposed to ethanol for 24 h while no difference when cells were
incubated with ethanol for 1 h.
Since mutation from Ile to Thr could change the hydropho-
bicity, we examined the hydrophilicity of transmembrane domain
6. This substitution increased hydrophilicity and likely altered the
conformation of transmembrane domain 6 (Figure 2D), which
might be account for the differential uptake activity in response to
prolonged ethanol treatment. We also examined possible
compensatory expression of other ENTs. The mRNA expression
levels of ENT2, 3, and 4 were similar between ENT1 null mice
and wild-type littermates (Figure S1). Thus, our results indicate
that the point mutation from isoleucine to threonine in ENT1
increases uptake activity upon prolonged ethanol exposure, which
might result in reduced extracellular nucleoside levels including
adenosine.
Increased Ethanol Withdrawal Seizure-like Phenotypes
and Decreased Adenosine Levels in ENT1 Null Mice
Previously, we found that a deficit of ENT1 in the mouse
increases glutamate neurotransmission by decreasing adenosine A1
receptor-mediated signaling in the brain [19] or decreased
glutamate uptake activity via excitatory amino acid transporter
type 2 (EAAT2) in astrocytes [21]. Our recent studies indicate that
increased glutamate neurotransmission in the striatum account for
some decreased ethanol sensitivity or increased ethanol drinking
behaviors in ENT1 null mice [20,27]. Since glutamate-mediated
hyperexcitable state could lead to ethanol withdrawal seizures
[6,28], we investigated whether prolonged ethanol exposure
increases withdrawal seizure-like phenotypes using a handling-
induced convulsion (HIC) assay for 2–30 h after cessation of
ethanol exposure. As shown in Figure 3A, ENT1 null mice showed
Figure 2. Prolonged Ethanol Exposure Increases Nucleoside Uptake Activity of ENT1-216Thr Compared to ENT1-216Ile. (A) [3H]
NBMPR bindings demonstrated reduction of Kd in the ENT1-216Ile and -216Thr in MEF cells. (B–C) Prolonged (24 h) ethanol exposure, but not acute
exposure (1 h) to ethanol significantly increased the uptakes of adenosine (B) as well as inosine (C) in ENT1-216Thr compared to ENT1-216Ile
(*P,0.05, two-tailed t-test). All data are expressed as mean 6 SEM. (D) Increased hydrophilicity in the helical wheel projection of ENT1-216Thr
transmembrane domain 6 in the ExPASy (www.ca.expasy.org). The substitution of 216Ile to 216Thr showed decreased hydrophobicity by 5.2 using
Kyte-Doolittle scale (4.5 vs. 20.7) and increased hydrophilicity by 1.4 using Hopp-Woods scale (21.8 vs. 20.4). Green color represents neutral amino
acid residues, red and blue color demonstrates hydrophobic and hydrophilic residues, respectively.
doi:10.1371/journal.pone.0016331.g002
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a significant increased HIC compared to wild-type littermates
[F(1,112) = 14.12, P,0.001] and time [F(6,112) = 6.72, P,0.001]
effects, without a significant interaction between genotype and
time. Further analysis of area under the curve also showed that
ENT1 null mice are more susceptible to alcohol withdrawal
seizures compared to wild-type mice (Figure 3A). Since striatal
adenosine receptors are implicated in ethanol-induced withdrawal
seizures [13], we measured total adenosine levels in the striatum
using tandem mass spectrometry (Figure 3B). Consistent with our
electrophysiology data, we found that adenosine levels were
significantly reduced in ENT1 null mice compared to wild-type
littermates (P,0.05). These results suggest that deficiency of
ENT1 decreases adenosine levels in the striatum, which is
implicated in vulnerability to alcohol withdrawal seizures.
Association of ENT1-216Thr with Alcoholism and the
History of Alcohol Withdrawal Seizures
We confirmed the presence of the 647C allele, which encodes
the ENT1-216Thr variant by resequencing of PCR-amplificons
(Table S1) from 50 alcoholic subjects. The other identified variants
were located in non-coding regions, and none of the variants in the
intron regions were located in putative sites for alternative splicing
(Table S2 and Figure S2). We then genotyped the 647C
(Ile216Thr) SNP in 140 additional DNA samples from alcohol-
dependent subjects of European descent (total n=190) recruited at
the Mayo Clinic in Rochester, Minnesota and 95 DNA samples
from self-reported non-alcoholics of European descent available
from the Coriell Institute (Camden, NJ). A second sample of 351
alcohol-dependent subjects and 416 non-alcoholic controls from
Munich, Germany was also genotyped for this SNP. Clinical
characteristics of the study subjects are summarized in Table S3.
The ENT1 647T/C (Ile216Thr) SNP was successfully genotyped
with a call rate of 100% for Mayo samples and 96% for Munich
samples. There were no significant departures from Hardy
Weinberg Equilibrium in either sample (P.0.05).
Our functional study in cells with the 216Thr variant of ENT1
protein revealed that prolonged exposure to ethanol resulted in a
statistically significant increase in the reuptake of adenosine
(Figure 2), which might be a molecular basis of ethanol withdrawal
seizures in humans because dysregulation of adenosine levels in
the brain is implicated in seizures [13,14,15]. Furthermore, we
found that mice lacking ENT1 gene, which mimics the hypo-
adenosine levels showed increased ethanol withdrawal seizures
(Figure 3). Therefore, we investigated the possibility of 647C SNP
(216Thr) contributing predisposition to alcoholism characterized
by alcohol withdrawal seizures. Among the total of 553 alcohol-
dependent subjects included in this study, 79 subjects had a history
of alcohol withdrawal seizures (Alc WS) without delirium tremens.
Despite the relatively small number of these subjects, focusing on
this phenotypically more homogeneous group may increase the
power to detect relevant genetic effects.
In the Mayo Clinic sample, the frequency of the ENT1-216Thr
variant was twice as high in the group of alcohol-dependent
subjects (MAF=0.032) compared to the Coriell controls
(MAF=0.016), but this difference was not statistically significant
(P = 0.27) (Table 1). Comparison between alcoholics with and
without a history of seizures showed a trend of association of
genotype with seizures [OR=3.2, 95% CI= (0.8,13.8); P = 0.09]
for Mayo subjects. However, there was no significant evidence of
association for the Munich subjects (P = 0.70) or the combined
group (P= 0.14), although a trend in the same direction was
observed [OR=1.3, 95% CI= (0.3,4.2) in the Munich sample and
OR=1.9, 95% CI= (0.8,4.6) in the combined analysis].
Interestingly, in the subgroup of alcohol-dependent subjects
with a history of withdrawal seizures (Alc WS), the frequency of
the minor allele was approximately four times higher
(MAF=0.064) compared to the non-alcoholic controls
(OR=4.51, 95% CI= (1.02,19.9); P = 0.047). Similar analyses
were then performed in the sample of Munich subjects (Table 1).
Although no statistically significant associations were observed in
this independent sample (P = 0.41), a trend in the same direction
was observed, with the rare ENT1-216Thr allele being associated
with increased risk of alcoholism with alcohol withdrawal seizures
[OR=1.69, 95% CI= (0.47, 5.99)]. Analysis of the combined
Mayo Clinic and Munich samples suggest that the minor ENT1-
216Thr allele is more common in alcoholics than in non-
alcoholics, and even more common among alcohol dependent
subjects with a history of withdrawal seizures, with an odds ratio of
2.51 [95% CI= (1.03, 6.12), P = 0.042] for alcoholism with
withdrawal seizures.
Discussion
This study suggests that a functional variant of human ENT1
gene might contribute to alcoholism with with increased risk of
alcohol withdrawal seizures. A recent human study of screening
Figure 3. The Absence of ENT1 Increases the Development of
Alcohol Withdrawal Seizure in Mice. (A) Handling induced
convulsion scores during the 30 h-period following removal from
ethanol vapor chambers. ENT1 null mice had higher scores than wild
type mice at 8 h after the ethanol withdrawal (*P,0.05, Tukey test).
Area under the curve analysis also shows the increased withdrawal
seizure in ENT1-null mice compared to wild-type littermates (*P,0.05,
two-tailed t-test). For each genotype, n= 9. (B) Reduced adenosine
levels in the striatum of ENT1 null mice compared to wild-type
littermates (*P,0.05, two-tailed t-test). For each genotype, n= 8. All
data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0016331.g003
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with 1350 variants in 130 genes demonstrated that one genetic
variant (rs731780) located in an intron of ENT1 (SLC29A1)
showed a significant association with heroin addiction in an
African-American population [29], attesting for clinical implica-
tion of ENT1 in alcohol use disorders and other substance
addictions.
Our functional studies using primary cultured cells with the
216Thr variant of ENT1 protein revealed that prolonged exposure
to ethanol resulted in a statistically significant increase in the
reuptake of adenosine. If the 647 T/C substitution displays the
same effect in neuronal cells (increasing uptake activity upon
prolonged alcohol exposure), it may cause reduced extracellular
adenosine levels and subsequent increase of glutamate tone in the
brain, which might be a molecular basis of ethanol withdrawal
seizures in humans. Consistently, agonists of both adenosine A1
and A2A receptors [13] and NMDA receptor antagonist [28] are
known to reduce ethanol-induced withdrawal seizures in mice.
Previously, we observed decreased adenosine tones in ENT1-null
mice [19], which contribute to decreased levels of ethanol response
and excessive alcohol consumption along with increased glutamate
neurotransmission in the striatum [19]. Striatal glutamate
signaling is known to be involved in ethanol withdrawal seizure-
like phenotype [28]. Interestingly, our results indicate that
increased uptake function of ENT1-216Thr variant upon alcohol
exposure could reduce extracellular or synaptic adenosine levels.
Controversially, absence of ENT1 also appears to decrease
extracellular adenosine levels in the brain. Since ENT1 is a
bidirectional transporter for nucleosides including adenosine and
inosine [7], ablation of the ENT1 gene would significantly slow
down dynamics of adenosine exchange across the plasma
membrane, which may result in low levels of extracellular
adenosine and reduced adenosine A1 receptor’s function in mice
[19]. Paradoxically, therefore, increased uptake activity of ENT1
could have a similar consequence as in ENT1 null mice.
Moreover, increased alcohol withdrawal seizures in ENT1 null
mice extend the phenotypic similarity between ENT1 null mice
model and the clinical presentation of alcohol dependence. A
possible explanation of the relationships between decreased
adenosine neurotransmission, increased alcohol consumption as
well as susceptibility to alcohol withdrawal seizure, is presented in
Figure 4.
The functional analysis of the ENT1-216Thr in yeast showed
no significant differences in basal [3H] inosine uptake by
nucleoside transporter inhibitors such as ribavirin, cytarabine,
and gemcitabine [23]. Although the uptake activities were tested in
yeast inactivated endogenous nucleoside transporter, FUI1, it has
certain limitations to examine the role of mammalian plasma
membrane transporter because of different membrane structure,
Table 1. Association of Ile216Thr Variant with the Phenotypes of Alcohol Dependence in Human Subjects
Site Groups Subject (N) c647 Genotype (N) Minor Allele Odds Ratio Logistic Regression
TT TC CC Frequency (95% CI) P value*
Mayo Non Alc** 95 92 3 0 0.016 – –
Alc-All 190 178 12 0 0.032 2.07 (0.57,7.51) 0.270
Alc WS*** 39 34 5 0 0.064 4.51 (1.02,19.90) 0.047
Munich Non Alc 416 397 19 0 0.023 – –
Alc-All 351 331 20 0 0.028 1.26 (0.66,2.41) 0.48
Alc WS*** 40 37 3 0 0.038 1.69 (0.47,5.99) 0.41
Combined Non Alc 511 489 22 0 0.022 – –
Alc-All 541 509 32 0 0.030 1.41 (0.80,2.47) 0.240
Alc WS*** 79 71 8 0 0.051 2.51 (1.03,6.12) 0.042
*P values indicate the comparison between each subgroup versus non-alcoholic control (Non Alc).
**In Mayo sample, non-alcoholics (Non-Alc) from Coriell Instutitue are self-reported non-alcoholics.
In Munich sample, Non-Alc recruited through an interview as described in the Method section.
***Alc WS denotes that subgroup of alcohol-dependent subjects (Alc-All) with alcohol withdrawal seizures.
doi:10.1371/journal.pone.0016331.t001
Figure 4. Simplied Schematic Mechanisms of ENT1-Mediated Signaling and Increased Genetic Susceptibility of ENT1-216Thr in
Alcohol Withdrawal Seizure. Prolonged ethanol exposure increases uptake activity of ENT1-216Thr compared to ENT1-216Ile, which lead to
reduction of extracellular adenosine levels.
doi:10.1371/journal.pone.0016331.g004
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intracellular kinases, and posttranslational modification such as
glycosylation which could alter the transporting activity of ENT1.
In our study, therefore, we examined the function of ENT1-
216Thr in primary cultured fibroblast cells (MEF), which were
isolated from ENT1 null mice to rule out possible complications of
endogenous ENT1 expression. Moreover, mRNA expression
levels of ENT2, 3, and 4, were similar in MEF cells derived from
ENT1 null and wild type littermates, indicating that the result was
not due to compensatory effects of other ENTs. Also, we found
similar plasma membrane expression between ENT1-216Ile and
216Thr in MEF cells, suggesting that membrane trafficking is not
the main factor for transporter activity.
The ENT1-216Thr variant exhibited an increased Kd value
compared to that of the wild type ENT1-216Ile. This mutation may
alter the folding of ENT1, thereby reducing the uptake and binding
activity of the transporter. Also, the increased hydrophilicity in
transmembrane domains 3 through 6 of ENT1 might alter
nucleoside and its analog’s transport [24,25]. The increased
hydrophilicity [30] and decreased hydrophobicity [31] values in
the helical wheel projection of transmembrane 6 in ENT1 suggest
that the substitution from isoleucine to threonine likely changes the
conformation of transmembrane domain 6. Subsequently, the
threonine residue in the transmembrane domain 6 could alter the
third intracellular loop of ENT1, which contains several phosphor-
ylation sites for protein kinase C (PKC), especially PKCd or e
[32,33], and casein kinase 2 (CK2) [34]. In vitro studies showed a
down-regulation of PKCd or e decrease ENT1 dependent uptake
activity [32]. Interestingly, in cultured neural cells, chronic ethanol
exposure increases levels of PKCd or e [35], suggesting that
increased uptake activity of ENT1-216Thr in response to chronic
ethanol exposure, in part, could be mediated by increased PKCd or
e activity. Since recent findings demonstrated that mice lacking
PKCe consume less alcohol and display increased sensitivity to
acute intoxicating effects of alcohol [36,37], while PKCd null mice
show decreased sensitivity to alcohol [38], it is possible that
upregulation of PKCe might be responsible for increased uptake
activity of ENT1-216Thr compared to that of ENT1-216Ile.
Ethanol induced increased uptake activity both for [3H]
adenosine and [3H] inosine in ENT1-216Thr, which suggests
that ethanol may regulate ENT1 function specifically as
demonstrated by several in vitro studies [17]. Although we observed
that an increase of inosine uptake (35.8%) is higher than adenosine
uptake (13.8%), this difference might be due to the nucleoside
stability since the half-life of adenosine is relatively short (10–
30 sec) compared to other nucleosides [39,40]. In cultured cells, it
has been known that acute ethanol exposure increases extracel-
lular adenosine by inhibiting ENT1 uptake activity [17], thereby
mediating ataxic or sedative effects of ethanol through adenosine
A1 and A2A receptors [7]. However, chronic ethanol exposure
desensitized the adenosine increase by ENT1 [41], which could
contribute to ethanol tolerance. We found that the decreased
adenosine activity observed in ENT1 null mice appears to be
similar to that of chronic ethanol-induced increase of uptake
activity in ENT1-216Thr. Consistently, ENT1 null mice and
human alcohol-dependent subjects who carry ENT1-216Thr are
able to consume higher amounts of alcohol and are susceptible to
ethanol-induced withdrawal seizures (Figure 4). Deletion of the
ENT1 gene in mice mimics the state of chronic ethanol exposure,
showing decreased levels of ethanol response and excessive alcohol
consumption along with decreased synaptic adenosine function
and increased glutamate neurotransmission [19,20].
Alcoholism is a complex multifactorial disease with genetic and
environmental components. Identification of contributing factors
is challenging, as the effect size of each contribution is likely to be
modest. It is expected that focusing on the most severe cases of
alcoholism may increase the power to detect genetic effects [42].
Presence of seizures during alcohol withdrawal in mice is widely
considered an indicator of severity of alcohol withdrawal and
increased glutamate levels [43]. In humans, presence of seizures is
also regarded as a sign of severe withdrawal and advanced stage of
alcoholism [44,45,46]. Thus, selection of this phenotype is
reasonable from both genetic and pathophysiological points of
view. Consistent with our hypothesis, the 647C variant of the
human ENT1 gene was found to be associated with alcoholism
with the history of alcohol withdrawal seizures in our first human
sample. This same trend was observed in the replication sample
but not at a statistically significant level. We performed analysis of
the combined data from the two sites using logistic regression with
a ‘‘site’’ covariate. We also analyzed the data from the two samples
using meta-analysis, which led to similar results with OR (95%
CI) = 2.55 (0.97–6.67), P = 0.056.
The human association component of our study is not free from
limitations, which include retrospective data collection and reliance
on self-report. The retrospective study design precluded us from
matching alcoholic study groups on a number of potentially
important parameters. Retrospective data collection also poses the
risk that important clinical information may be misrepresented.
However, among the many possible phenotypes in alcohol
dependence, the withdrawal seizure is one of the most obvious
and physically noticeable phenotypes for which patients’ self-report
can be used reliably. Although not perfect, retrospective data
collection is commonly used in clinical and genetic studies focused
on this phenotype [46]. In an effort to increase the reliability of our
data we only included subjects who were able to describe the
critically important components of the seizure episode (seizure
activity with loss of consciousness) based on information provided by
witnesses. Another limitation is the difference between study
samples. Subjects recruited in Germany were younger and reported
higher alcohol consumption (both on average and maximum per
24 h). In addition, screening for presence of the medical and/or
neurological causes for seizures during index episode was performed
for subjects recruited in the Mayo sample. These discrepancies
between the two study samples might have diminished our ability to
detect association between ENT1 647C variant and alcohol
withdrawal seizures at a statistically significant level. Nevertheless,
combined results from the two independent recruiting sites indicate
that the ENT1-216Thr variant may contribute to the risk of
alcoholism with withdrawal seizures in humans.
In summary, our studies suggest that ENT1-216Thr appears to
contribute to the genetic predisposition to alcoholism with an
increased risk of withdrawal-related seizures. Considering the
complexity of genetic and environmental contribution to alcohol
dependence, this finding is a step towards understanding the
genetic predisposition to alcohol-related phenotypes.
Materials and Methods
Ethics Statement
This study conducted in compliance with the Code of Ethics of
the World Medical Association (Declaration pf Helsinki) and the
standard established by the Institutional Review Board of the
Mayo Clinic Rochester, Martin-Luther-University and Ludwig-
Maximilians University. All subjects provided written informed
consent approved by the Institutional Review Board and Ethics
Committee of each participating institution. Animal care and
handling procedures were approved by Mayo Clinic Institutional
Animal Care (approved protocol number: A23808) and Use
Committees in accordance with NIH guidelines.
ENT1 and Alcohol Withdrawal Seizures
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Mice
ENT1 null mice were generated as described [19]. We used
mice having a ,50% C57BL/6J and ,50% 129X1/SvJ genetic
background to minimize strain-specific effects as recommended
[47,48]. We used 8–16 week old male mice for all experiments.
Mice were housed in standard Plexiglas cages with food and water
ad libitum. The colony room was maintained on a 12 h light/dark
cycle with lights on at 6:00 a.m.
Primary Cell Culture and Transfection
Primary MEF cells were prepared from ENT1 null mice at
embryonic day 13.5 postcoitum. MEF cells were grown in DMEM
supplemented with 10% heat-inactivated fetal bovine serum and
100 mg/ml penicillin/streptomycin at 37uC in a water-saturated
atmosphere under 5% CO2 in air. Cells were transfected using
Lipofectamine and PLUS reagents (Invitrogen, Carlsbad, CA).
Site-directed Mutagenesis
Human cDNA of ENT1, which is cloned into pcDNA3, was
provided kindly by Dr. Pastor-Anglada M. (University of
Barcelona, Spain). A point mutation was generated using
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA). The cDNAs of 216Ile wild type and 216Thr variant were
subcloned into pCMV-Myc (Clontech, Mountain View, CA) and
pEGFP-N1 (Clontech) respectively.
Expression Measurements
After transfection, 1 mg of RNA was converted to cDNA by
reverse transcription reaction using Omniscript (Qiagen, Valencia,
CA) and random hexamer primers. Realtime PCR was performed
by IQ SYBR Green Supermix (Bio-Rad, Hercules, CA) using
MyiQ realtime PCR detection system (Bio-Rad). Relative mRNA
expressions, which were normalized by beta-actin were calculated
by using the 22DDCt method [49]. We used anti-myc antibodies to
examine hENT1 protein since no specific antibodies are available
for mouse or human ENT1. To determine the protein expression
by Western blot, proteins prepared from transfected cells were
separated on 4–12% Bis-Tris gels. Proteins in gels were transferred
to nitrocellulose membranes, which were incubated for 2 h at 4uC
in blocking buffer containing 5% BSA and 0.05% Tween 20 in
Tris-buffered saline (10 mM Tris, pH 7.5, and 100 mM NaCl).
The membranes were incubated overnight at 4uC with c-Myc
antibody (1:1,000, Clontech, supplied with c-Myc vector) and then
re-probed with GAPDH antibody (1:300, Chemicon, Temecula,
CA) to assess the protein amount.
Fluorescence Microscopy
MEF cells were transfected and grown on coverglasses and then
fixed in 2% paraformaldehyde for 30 min at room temperature. For
plasma membrane marker, sodium potassium ATPase was used.
After blocking in 5% goat serum, the slides were incubated for 1 h
at room temperature with primary sodium potassium ATPase
antibody for plasmamembrane marker (1:100, Abcam, Cambridge,
MA) and secondary Rhodamine RedTM-X goat anti–mouse IgG
antibody (1:100, Invitrogen). Fluorescence was analyzed using a
LSM510 confocal microscope (Carl Zeiss, Germany). The green
and red fluorescence were quantified using Image J (NIH).
Uptake Assays
MEF cells were transfected with each construct of hENT1-
216Thr and 216Ile. The [3H] nucleoside uptake assay was
conducted in phosphate-buffered saline (PBS) containing 1 mCi
[3H] nucleoside/ml at room temperature for 30 min in the presence
or absence of ENT1-specific inhibitor (NBMPR). Uptake was
terminated by adding ice-cold PBS containing 10 mMNBMPR and
cells were then solubilized in 1% Triton X-100. An aliquot was
taken for measurement of radioactivity and protein content using,
respectively, a liquid scintillation counting and protein assay.
[3H] NBMPR Binding
The transfected MEF cells were incubated with [3H] NBMPR
with and without competitive ENT1-specific inhibitor dilazep
(10 mM) for 45 min at room temperature. Cells were washed with
cold Tris-HCl (10 mM, pH 7.4), and then solubilized in 1%
Triton X-100. An aliquot was taken for measurement of
radioactivity and protein content using, respectively, a liquid
scintillation counting and protein assay. Specific binding was
defined as total minus nonspecific binding. The Kd and Bmax values
were calculated from nonlinear curve fits (Prism 4, GraphPad
Software, San Diego, CA).
Handling-Induced Convulsion (HIC) Score
To examine whether absence of ENT1 alters ethanol
withdrawal seizures, we measured handling induced convulsions
(HIC) scored up to 30 h after 3 d (16 h/day) of ethanol exposure
in vapor chamber (7–10 mg/L of air, 150,200 mg/dl blood
ethanol levels) as described [50].
Adenosine Levels
Wemeasured striatal adenosine levels using a modified LC/MS/
MS (liquid chromatography and tendem mass spectrometry)
method as described [51]. Briefly, striatal tissues were heated to
70uC for 20 min followed by addition of ice-cold 10 mM HCl and
centrifuged to precipitate proteins at 25,000 g for 10 min at 4uC.
Followed by, supernatants were desalted using Oasis HLB sample
cartridges (Waters, Malford, MA) and then each sample was diluted
(200 ng/ml protein) and stored at 220uC until use. 2 mg samples
(10 ml) were analyzed using Paradigm MS4B HPLC (Michrom
Bioresources, Auburn, CA) coupled with a TSQ Quantum Ultima
MS triple quadrupole mass spectrometer (Thermo Fisher Scientific,
Waltham, MA). Separation was performed with Atlantis dC18
NanoEase Column (3 mm, 300 mm6100 mm) with 5 ml/min flow
rate. Using Multiple Reaction Monitoring (MRM) scans, adenosine
levels were quantified by measuring dissociation of adenosine (268
Da) to fragmented compound (136 Da) in 20 eV collision energy.
Human Subjects, DNA Sequencing and Genotyping
Human subjects were recruited from Mayo Clinic Rochester and
Munich, Germany (see detailed description in the Methods S1). To
confirm genetic variation in human ENT1, new pairs of primers were
generated for all exons of the human ENT1 gene (Table S1),
including about 100 bp of exon-intron boundaries based on the
chromosome 6p21.1 genomic sequence (NT_007592.15). Genomic
DNA was isolated from blood of patients using AutoPure LS (Gentra,
Minneapolis, MN). The coding sequence of the human ENT1 was
compared with the GenBank accession number NM_004955. All the
exons and introns were PCR amplified and sequenced using ABI
3730xl automated sequencer (Applied Biosystems). Sequence variants
were then screened by Mutation Surveyor version 2.2 (Softgenetics,
PA). For 647C (ENT1-216Thr) genotyping, TaqMan assay was
employed using the ABI prism 7900HT sequence detection system
(Applied Biosystems, Foster City, CA).
Statistics
Data are presented as mean 6 SEM (standard error of the
mean). Data were examined by two-tailed t-test or two-way
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ANOVA (ethanol-induced withdrawal seizure) followed by a
Tukey post-hoc test for comparison among different treatment
groups. For statistical analysis for human genomics, see the
Methods S1. Results were considered significantly different when
P,0.05.
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